Align Technology Appoints Paul Clancy and Ian Bell to Board of Directors

By Dr. Andrea Joy Smith

Align Technology has appointed Paul J. Clancy to its Board of Directors effective immediately and Ian Bell to the Board effective Dec. 10, 2026.


This Article is Sponsored by Dental Media Now

TEMPE, Ariz. & SAN JOSE, Calif., Nov. 19, 2026, (DrAndreaJoySmith.com) — Dental technology company Align Technology has appointed Paul J. Clancy to its Board of Directors effective immediately and Ian Bell to the Board effective Dec. 10.

Latest Blogs

•

Latest Blogs •

Clancy is a former Executive Vice President and Chief Financial Officer of Alexion Pharmaceuticals and Biogen, while Bell currently serves as Senior Vice President and Chief Operating Officer of Alcon.

“We are pleased to welcome Paul Clancy to our Board and look forward to the addition of Ian Bell in December. Paul and Ian bring significant global healthcare, financial, innovation and operational leadership experience that will complement the strengths of Align’s Board. Paul’s deep financial and strategic leadership in the biopharmaceutical industry, together with Ian’s broad perspective across commercial, manufacturing, quality and regulatory operations and his experience leading innovation-driven businesses, will be valuable as we continue to execute our strategy and drive long-term growth,” said Kevin Conroy, Chairman of the Board of Align Technology.

Clancy brings more than 30 years of strategic, financial and operational leadership experience, primarily in biotechnology and pharmaceuticals.

He served as Executive Vice President and Chief Financial Officer of Alexion Pharmaceuticals from 2017 to 2019 and remained a Senior Advisor through July 2020. Before that, he served as Executive Vice President and Chief Financial Officer of Biogen from 2007 to 2017.

Clancy joined Biogen in 2001 as Vice President of U.S. Marketing and later held roles including Vice President of Portfolio Management and Senior Vice President of Finance. Earlier in his career, he spent 13 years at PepsiCo in finance, strategy and general management positions.

He currently serves on the Board of Directors of Incyte Corporation and as Chair of the Board of Sionna Therapeutics. He is also an Executive Fellow at Harvard Business School.

Bell currently oversees Alcon’s commercial, manufacturing, quality and regulatory operations as Senior Vice President and Chief Operating Officer.

Before assuming that role in 2024, he served as President, Global Business & Innovation, where he led product development across Alcon’s surgical, vision care and digital health businesses. His previous positions include President, International and President of Alcon’s Europe, Middle East and Africa region.

Before joining Alcon in 2016, Bell held senior leadership positions at Hospira and Allergan and began his career at GlaxoSmithKline.

Clancy and Bell will both be included in Align Technology’s slate of Director nominees for its 2027 Annual Meeting of Shareholders.

Following Bell’s appointment, the Board will consist of 13 Directors until Dec. 31, when the previously announced retirement of C. Raymond Larkin Jr. will reduce the Board to 12 members.

Align Technology develops and manufactures the Invisalign clear aligner system, iTero intraoral scanners and exocad CAD/CAM software for digital orthodontics and restorative dentistry.

For more information, visit www.aligntech.com.

Source: Align Technology

Next
Next

MassMutual South Carolina Welcomes Bluewater Dental Advisors